TEL AVIV (MarketWatch) -- Teva Pharmaceutical Industries Ltd. lifted its 2007 earnings estimate Monday as the generic drugmaker launched a version of the Protonix acid-reflux treatment.
Teva raised its full-year outlook after announcing its launch of generic equivalents to Wyeth's Protonix, an acid-reflux treatment. Wyeth said it will pursue a patent-infringement claim for lost profits and other damages.